Figures
- FIGURE 1
Overall survival (OS) a and b) from second-line chemotherapy and c and d) from first-line chemotherapy of a and c) nonsmall cell lung cancer (NSCLC) and b and d) small cell lung cancer (SCLC), respectively. MST: median survival time.
Tables
- TABLE 1
The incidence of acute exacerbation (AEx) of idiopathic interstitial pneumonias related to each first-line chemotherapy regimen
Regimen Patients AEx Carboplatin+paclitaxel 140 (35.4%) 12 (8.6%) Carboplatin+etoposide 82 (20.7%) 3 (3.7%) Cisplatin+etoposide 38 (9.6%) 4 (10.5%) Vinorelbine 30 (7.6%) 8 (26.7%) Cisplatin+UFT 17 (4.3%) 5 (29.4%) Carboplatin+vinorelbine 10 (2.5%) 0 (0%) Cisplatin+vinorelbine 9 (2.3%) 2 (22.2%) Docetaxel 7 (1.8%) 1 (14.3%) Carboplatin+docetaxel 6 (1.5%) 4 (66.7%) Cisplatin+docetaxel 6 (1.5%) 1 (1.7%) Gefitinib 6 (1.5%) 5 (83.3%) Others 51 10 (19.6%) Total 396 52 (13.1%) UFT: tegafur-uracil.
- TABLE 2
The association between acute exacerbation (AEx) of idiopathic interstitial pneumonias and each suspected cytotoxic agent
Agents Patients AEx Cisplatin 91 15 (16.5%) Carboplatin 250 20 (8.0%) Etoposide 124 7 (5.6%) Paclitaxel 146 18 (12.3%) Vinorelbine 51 10 (19.6%) Docetaxel 19 6 (31.6%) Gemcitabine 6 1 (16.7%) Vindesine 17 1 (5.9%) UFT 17 5 (29.4%) Platinum-based regimen 341 35 (10.3%) Nonplatinum-based regimen# 49 13 (26.5%) UFT: tegafur-uracil. #: gefitinib was excluded.
- TABLE 3
Patient characteristics of the analysis of second-line chemotherapy
AEAS# SAS# Subjects 278 180 Age years median (range) 69 (38–85) 69 (38–83) Sex Male 239 (86.0%) 154 (85.6%) Female 39 (14.0%) 26 (14.4%) Histology AdC 101 (36.3%) 70 (38.9%) SqCC 70 (25.2%) 51 (28.3%) AdSqC 1 (0.4%) 1 (0.6%) NSCLC (NOS) 32 (11.5%) 14 (7.8%) SmCC 74 (26.6%) 44 (24.4%) Pattern of IIPs UIP 146 (52.5%) 89 (49.4%) Non-UIP 103 (37.1%) 66 (36.7%) Unclassified 29 (10.4%) 25 (13.9%) AEAS: acute exacerbation analysis set; SAS: survival analysis set; AdC: adenocarcinoma; SqCC: squamous cell carcinoma; AdSqC: adenosquamous carcinoma; NSCLC: nonsmall cell lung cancer; NOS: not otherwise specified; SmCC: small cell carcinoma; IIP: idiopathic interstitial pneumonia; UIP: usual interstitial pneumonia. #: AEAS was evaluated for acute exacerbation and objective response by second-line chemotherapy; SAS consisted of patients for which analysable survival information could be obtained.
- TABLE 4
The incidence of acute exacerbation (AEx) of idiopathic interstitial pneumonias related to each second-line chemotherapy regimen
Regimen Patients AEx Docetaxel 72 (25.9%) 11 (15.3%) Carboplatin+paclitaxel 31 (11.1%) 3 (9.7%) Vinorelbine 24 (8.6%) 6 (25%) Pemetrexed 21 (7.6%) 6 (28.6%) Amrubicin 18 (6.5%) 6 (33.3%) S-1 14 (5.3%) 0 (0%) Nogitecan 13 (4.9%) 3 (23.1%) Carboplatin+etoposide 15 (5.4%) 0 (0%) EGFR-TKIs 9 (3.2%) 4 (44.4%) Paclitaxel 7 (2.5%) 1 (14.3%) Cisplatin+vinorelbine 6 (2.2%) 0 (0%) Irinotecan 6 (2.2%) 0 (0%) Others 42 5 (12.5%) Total 278 45 (16.2%) EGFR-TKI: epidermal growth factor receptor tyrosine kinase inhibitor.
- TABLE 5
The response to second-line chemotherapy
NSCLC SCLC Subjects 204 74 Number of cycles median (range) 3 (1–22) 3 (1–6) Response CR 0 1 PR 15 18 SD 68 17 PD 83 23 NE 38 15 Overall response rate n 15 19 % (95% CI) 7.4 (3.8–10.9) 25.7 (15.7–38.8) Disease control rate n 83 36 % (95% CI) 40.7 (33.9–49.6) 48.6 (34.6–60.9) Introduction rate of third-line chemotherapy 46.6% 44.6% NSCLC: nonsmall cell lung cancer; SCLC: small cell lung cancer; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; NE: not evaluated.
Supplementary Material
Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.
Supplementary material 00184-2019.SUPPLEMENT
